Bone Health and Osteoporosis in Non-Ambulatory Children With CP

Reduced bone density is one of the most common but often invisible complications of cerebral palsy in non-ambulatory children. This article explains why bones are at risk, how it is monitored, what prevention looks like, and when bisphosphonate therapy is considered.

Why Bones Are at Risk in Non-Ambulatory CP

Bone is dynamic tissue. It builds itself in response to mechanical loading: walking, jumping, weight-bearing. Without these stimuli, the body remodels less bone formation and more bone resorption. The result is reduced bone mineral density and structural weakness. Children with CP who do not walk often have other contributing factors:

• Limited dietary calcium and vitamin D
• Reduced sun exposure (less time outdoors)
• Anti-seizure medications (some affect vitamin D metabolism)
• Frequent illness limiting activity further
• Smaller body size and growth retardation
• Chronic inflammation from feeding difficulties or other conditions

The combination of these factors leaves bones substantially weaker than typically developing peers. Fractures can occur during routine activities (dressing, repositioning, therapy stretches) with little warning.

Monitoring: DEXA Scans

DEXA (Dual-Energy X-ray Absorptiometry) is the gold standard for measuring bone density. Pediatric DEXA programs typically:

• Begin scanning around age 6 to 8 in non-ambulatory CP children
• Repeat every 1 to 2 years to track trends
• Use lumbar spine and lateral distal femur regions (hip and spine standard sites for adults are often less reliable in CP)
• Compare to age-matched and sometimes height-matched normative data

Results are reported as Z-scores (comparison to age-matched peers). A Z-score below -2.0 is considered low bone density; below -2.5 with fractures is consistent with osteoporosis. Pediatric endocrinology or a bone health specialist usually interprets the results in context.

Prevention: Vitamin D, Calcium, and Standing

Foundational prevention strategies:

• Vitamin D: routine supplementation in non-ambulatory CP, often 1,000 to 2,000 IU daily. Test 25-OH vitamin D level annually and adjust dose. Many children need higher doses to maintain optimal levels.
• Calcium: from diet when possible (dairy, fortified foods); supplement when intake is inadequate.
• Standing programs: 30 to 60 minutes daily of weight-bearing in a standing frame from age 1 onward stimulates bone formation throughout childhood.
• Weight-bearing therapy: gait training, supported standing during transfers, and any safe weight-bearing position helps.
• Optimize nutrition: address underweight or growth failure, which compounds bone risk.
• Review epilepsy medications: phenytoin, phenobarbital, and others can affect vitamin D metabolism.

When Bisphosphonate Therapy Is Considered

For children with severe osteoporosis (very low bone density) or recurrent fractures despite preventive measures, bisphosphonate therapy is considered. The two most commonly used in pediatric CP are pamidronate (given IV every 3 to 4 months) and zoledronic acid (given IV every 6 to 12 months). They work by reducing bone resorption, allowing accumulation of bone density. Studies in pediatric CP show meaningful improvements in DEXA scores and reduced fracture rates with bisphosphonate therapy. Pediatric endocrinology or bone health teams manage treatment, including pre-treatment dental clearance (rare jaw concerns), calcium and vitamin D optimization, and post-infusion monitoring.

When Fractures Happen

Despite prevention, fractures still occur. Common patterns:

• Femur (thigh bone) fractures during transfers or stretching
• Tibia (shin) fractures during dressing or positioning
• Vertebral compression fractures, often without obvious trauma
• Sometimes fractures discovered incidentally during X-rays for other reasons

If a fracture occurs, treatment depends on location and severity. Most non-displaced fractures in CP children are managed with casting or splinting. Surgery is sometimes needed for displaced fractures. After a fracture, bone health evaluation is important: get DEXA, review vitamin D, and consider bisphosphonate therapy.

Long-Term Outlook

With appropriate prevention and treatment, fracture rates can be significantly reduced. Bisphosphonate therapy has substantially improved outcomes for severely affected children. The long-term goal is to maintain enough bone strength to allow safe care, prevent painful and functional consequences of fractures, and protect quality of life. This requires ongoing attention through childhood and adolescence: regular DEXA, vitamin D testing, optimized nutrition, and weight-bearing whenever possible.

Bone Health Action Plan

What every family of a non-ambulatory CP child should ensure.

What signs suggest a fracture?

Sudden swelling, fussiness with movement of a specific limb, refusal to bear weight, visible deformity, or unexplained pain after routine care. Parents and caregivers learn to recognize subtle signs over time. If a fracture is suspected, see the pediatrician or emergency room for X-rays. Many fractures heal well with appropriate care.

Are bisphosphonates safe long-term?

Pediatric bisphosphonate therapy has been used for decades with generally good safety. Pediatric endocrinology monitors for rare concerns including atypical fractures, jaw issues (very rare), and effects on growing bone. Treatment is usually given for several years then reassessed. Benefits substantially outweigh risks for children with severe osteoporosis or recurrent fractures.

Related reading for parents

• Standing frames for children with CP: types, benefits, and when to start
• Understanding and managing scoliosis in children with CP
• Hip surveillance for children with CP
• Epilepsy and cerebral palsy: what parents need to know
• Nutrition and weight gain for children with cerebral palsy